Antibody 0.5b to hiv-i gp 120 modified with toxic substance

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

167/140, 195/1.1

C12N 5/18 (2006.01) A61K 39/42 (2006.01) A61K 47/48 (2006.01) A61K 51/10 (2006.01)

Patent

CA 1339775

The present invention is directed to an antibody or fragment thereof, modified with a toxic substance capable of substantially inhibiting the growth of human cells infected with viruses, which is prepared by conjugating a substance capable of chemically and/or physically inducing cytotoxicity against human cells infected with HIV with an antibody or fragment thereof capable of specifically reacting with at least one antigen of said viruses, by using a pharmacologically inert substance as a carrier. The antibodies according to the present invention may be used, for example, in the diagnosis, prevention and curing of chronic disorders induced by viral infections, e.g AIDS and leukemia, since they are not only capable of inhibiting the growth of the virus-producing cells and capable of killing such cells but also are capable of neutralizing the viruses without inhibiting the growth of uninfected cells.

602214

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antibody 0.5b to hiv-i gp 120 modified with toxic substance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody 0.5b to hiv-i gp 120 modified with toxic substance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody 0.5b to hiv-i gp 120 modified with toxic substance will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1221224

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.